Women's Health

What Causes Restless Legs in Perimenopause with Hypothyroidism?

Restless legs syndrome (RLS) affects up to 26% of women in perimenopause — a rate nearly double that seen in age-matched men. When hypothyroidism is layered on top, the risk climbs further because low thyroid hormones, disrupted dopamine signaling, and falling estrogen all converge on the same neurological pathway. Getting the right diagnosis requires checking more than just your TSH.

Jared Murray ·Co-Founder & Head of Health Research, Ones · ·9 min read
restless legs syndromeperimenopausehypothyroidismwomen's healthsleep disorders
What Causes Restless Legs in Perimenopause with Hypothyroidism?

What Causes Restless Legs in Perimenopause with Hypothyroidism?

Yes, the combination genuinely amplifies the risk. Perimenopause lowers estrogen, which destabilizes dopamine signaling in the spinal cord — the same pathway that regulates leg sensations at rest. Hypothyroidism adds impaired iron metabolism, peripheral nerve slowing, and reduced dopamine receptor sensitivity. The exception: women whose thyroid is well-controlled and whose ferritin sits above 75 ng/mL often see symptoms resolve without RLS-specific treatment.

---

Why Perimenopause and Hypothyroidism Create a Perfect Storm for RLS

Restless legs syndrome is classified as a sensorimotor disorder driven primarily by dopaminergic dysfunction in the spinal cord and basal ganglia, with iron deficiency acting as a critical cofactor. Neither perimenopause nor hypothyroidism alone fully explains why so many women in their 40s and early 50s suddenly develop the unbearable urge to move their legs at night — but the overlap between the two conditions tells a clearer story.

Estrogen and dopamine are tightly coupled. Estrogen modulates D2 receptor density and dopamine transporter activity in the striatum. As estrogen fluctuates and ultimately declines through perimenopause, the dopaminergic tone in circuits governing sensory gating falls, lowering the threshold for the abnormal sensations characteristic of RLS (Manconi et al., Sleep Medicine Reviews 2012; PMID: 21641839).

Hypothyroidism disrupts iron homeostasis. Thyroid hormone is required for the synthesis of transferrin receptors on neurons. Hypothyroid states reduce the brain's capacity to take up iron even when serum ferritin appears adequate, effectively creating a state of functional brain iron deficiency that is not visible on a standard iron panel (Trotti & Bhowmik, Current Neurology and Neuroscience Reports 2017; PMID: 28421385).

Peripheral neuropathy compounds the picture. Even mild, subclinical hypothyroidism is associated with slowed peripheral nerve conduction. A 2018 cross-sectional study found that RLS prevalence was significantly higher in hypothyroid patients compared to euthyroid controls (45.5% vs. 20.9%), and the severity correlated with TSH levels independent of ferritin (Cakir et al., Sleep Medicine 2018; PMID: 30196264).

The result is a system under pressure from multiple directions simultaneously — which is why standard first-line advice like "take more iron" often fails to fully resolve symptoms in this population.

---

The Biomarkers That Actually Explain Your Symptoms

If you're in perimenopause with hypothyroidism and you're experiencing RLS, a TSH alone will not give you the full picture. The following panel gets clinicians much closer to the root cause.

Iron and Iron Storage

BiomarkerConventional "Normal"RLS-Relevant Target
Serum ferritin>12 ng/mL>75 ng/mL
Transferrin saturation20–50%>25%
Serum iron60–170 mcg/dLMid-to-upper range

The critical insight from the Johns Hopkins RLS clinic and replicated in European RLS guidelines is that brain iron deficiency correlates most strongly with ferritin below 75 ng/mL — a threshold well above what most labs flag as deficient (Allen et al., Sleep Medicine 2013; PMID: 23465553). Many women with perimenopause-related blood loss through irregular cycles arrive at their 40s with ferritin in the 20–40 ng/mL range, which looks "normal" on a lab report but is functionally insufficient for dopamine synthesis.

Thyroid Panel

A full thyroid panel is essential rather than TSH in isolation. Free T3 is particularly relevant because it is T3 — not T4 — that regulates transferrin receptor expression in neurons. Women on levothyroxine who have adequate T4 but suboptimal T3 conversion can remain functionally hypothyroid in neural tissue even with a normal TSH. If you're also experiencing symptoms like hair shedding or exhaustion alongside restless legs, a full panel including free T3, reverse T3, and thyroid antibodies gives your provider a much more accurate map.

  • TSH
  • Free T4
  • Free T3
  • Reverse T3
  • TPO antibodies (if Hashimoto's is suspected)

Dopamine Precursors and Cofactors

Dopamine synthesis requires iron (as a cofactor for tyrosine hydroxylase), vitamin B6 (pyridoxal-5-phosphate form), and folate. All three are commonly depleted in hypothyroid women due to impaired gut absorption and altered metabolic clearance. Homocysteine is a useful indirect marker — elevated homocysteine above 10 µmol/L suggests inadequate B-vitamin status and correlates with higher RLS severity in some observational data.

Magnesium

Magnesium deficiency is extremely common in perimenopause and contributes to restless legs through its role in NMDA receptor gating and neuromuscular excitability. Low magnesium amplifies the perception of uncomfortable sensations in peripheral nerves and reduces sleep quality independently. This often overlaps with other perimenopausal complaints — if you're also dealing with bloating or low mood, suboptimal magnesium is worth investigating across the board.

---

How Thyroid Dysfunction Specifically Worsens RLS Severity

It is worth separating the presence of RLS from its severity, because hypothyroidism appears to worsen the second more than the first.

In euthyroid women, perimenopausal RLS tends to be mild-to-moderate and closely follows the luteal phase of remaining cycles, suggesting a strong estrogen-progesterone driver. In hypothyroid women, the RLS pattern is more continuous, less cycle-linked, and more likely to involve periodic limb movements during sleep (PLMS) — involuntary leg jerks that the patient may not be aware of but that fragment sleep architecture dramatically.

A proposed mechanism is that reduced thyroid hormone signaling decreases the density of D2/D3 receptors in the striatum, compounding the estrogen-related receptor downregulation already occurring in perimenopause. The combined receptor deficit means that even normal dopamine release produces inadequate signal — the neurological equivalent of turning the volume down on two amplifiers simultaneously.

This also explains why some women in this overlap group find that iron supplementation alone provides only partial relief: they are addressing one input (dopamine cofactor availability) while two receptor-level deficits (estrogen-related and thyroid-related) remain unaddressed.

---

The Role of Progesterone

Progesterone, which falls steeply in early perimenopause often before estrogen does, has GABAergic properties through its conversion to allopregnanolone. GABA is an inhibitory neurotransmitter that suppresses the spinal cord sensory signals involved in RLS. As progesterone drops, the GABAergic brake on these signals weakens, and RLS symptoms that were previously subclinical can cross into clinical awareness.

This mechanism is consistent with the clinical observation that RLS in perimenopause is often worst in the second half of the night — a time when GABA-mediated sleep deepening is most needed and most impaired. It is also consistent with the well-documented worsening of RLS during the first trimester of pregnancy, when progesterone has not yet fully compensated for the increased demand (Manconi et al., PMID: 21641839).

---

Sleep Architecture and the Feedback Loop

RLS does not just cause uncomfortable sensations — it profoundly disrupts sleep architecture. PLMS-related arousals suppress slow-wave sleep (SWS) and reduce REM percentage. This matters for the perimenopause-hypothyroidism overlap for two reasons:

  1. Growth hormone and thyroid repair occur in SWS. Fragmented SWS impairs TSH pulsatility and reduces nocturnal GH secretion, which means poor sleep caused by RLS can worsen thyroid function, creating a worsening loop.
  2. Cortisol dysregulation. Chronic sleep fragmentation elevates nocturnal cortisol, which suppresses thyroid-releasing hormone at the hypothalamic level and further compromises T3 conversion in peripheral tissues.

This feedback loop is one reason why treating only the thyroid or only the RLS in this population produces incomplete results. For more on the interplay between thyroid function and daytime symptoms, see what causes hot flashes in perimenopause with hypothyroidism — the cortisol-thyroid connection runs through both symptom clusters.

---

A Targeted Supplement and Lifestyle Protocol

The protocol below is organized by mechanism and evidence tier. It is designed to complement — not replace — appropriate thyroid medication management by a physician.

Tier 1: Address Iron Status (if ferritin < 75 ng/mL)

  1. Confirm ferritin, transferrin saturation, and CRP before supplementing — inflammation falsely elevates ferritin.
  2. Use iron bisglycinate (25–65 mg elemental iron) on an empty stomach with 500 mg vitamin C to maximize absorption.
  3. Recheck ferritin at 8–12 weeks; target ≥75 ng/mL, not simply "normal range."
  4. Avoid calcium supplements and thyroid medication within 4 hours of iron dosing — both block absorption.

Tier 2: Optimize Thyroid Conversion

  1. Discuss free T3 and reverse T3 with your prescribing physician. Poor T3 availability is a significant but often underdiagnosed driver in this group.
  2. Selenium (selenomethionine 200 mcg/day) supports 5'-deiodinase enzyme activity, which converts T4 to active T3, and has demonstrated benefit in Hashimoto's patients in multiple trials.
  3. Zinc supports thyroid receptor function and is frequently depleted in perimenopause.

Tier 3: Support Dopaminergic and GABAergic Tone

  1. Magnesium glycinate 300–400 mg taken 1–2 hours before bed — the glycinate form is best tolerated and crosses the blood-brain barrier more efficiently than oxide forms.
  2. Vitamin B6 as pyridoxal-5-phosphate (P5P) 25–50 mg daily supports dopamine synthesis via DOPA decarboxylase.
  3. Folate (methylfolate, not folic acid, particularly if MTHFR variants are suspected) 400–800 mcg supports the methylation cycle required for neurotransmitter synthesis.

Tier 4: Sleep Hygiene Specific to RLS

  • Avoid caffeine after noon — adenosine antagonism at night worsens periodic limb movements.
  • Warm (not hot) baths or leg stretches before bed reduce acute symptom severity in observational studies.
  • Keep bedroom temperature below 68°F — heat worsens RLS in most patients.
  • Avoid antihistamines and older antidepressants (especially SSRIs and tricyclics) where clinically possible — both are known RLS aggravators.

---

What This Means for Your Formula

For women managing this specific overlap, a personalized formula needs to address at least three distinct mechanisms — not just pour in a generic multivitamin. Here is where Ones' approach adds precision:

Magnesium Complex — Ones includes a magnesium blend that uses highly bioavailable forms, dosed in the clinical range to support neuromuscular regulation and sleep quality. For RLS specifically, magnesium's role in NMDA gating and muscle nerve excitability is distinct from its better-known role in energy metabolism.

Thyroid Support (System Blend) — Ones' Thyroid Support blend is designed around the cofactors that support healthy thyroid hormone synthesis and T4-to-T3 conversion, including selenium and zinc at clinically relevant doses. For women in the perimenopause-hypothyroidism overlap, supporting conversion efficiency at the enzymatic level is as important as the thyroid medication itself.

Zinc and B6 (P5P form) — Both appear as individual actives in Ones formulas where the AI identifies depletion signals in blood work or symptom history. Because RLS severity correlates with dopamine cofactor status, targeted dosing of these two nutrients — rather than the token amounts in most multivitamins — is clinically meaningful.

Ones' AI practitioner also reviews the full biomarker picture, which means it can flag a ferritin of 38 ng/mL as functionally significant for RLS risk even when a standard lab marks it "within range" — the kind of nuance that often gets missed in a 15-minute GP appointment.

---

Key Takeaways

  • Restless legs syndrome in perimenopause is driven by declining estrogen's effect on dopamine receptor density, compounding any pre-existing dopaminergic dysfunction from hypothyroidism.
  • Hypothyroidism worsens RLS by impairing brain iron uptake, slowing peripheral nerve conduction, and reducing D2/D3 receptor sensitivity — independent of ferritin levels.
  • The ferritin target for RLS symptom resolution is ≥75 ng/mL, not the laboratory "normal" cutoff of 12 ng/mL; many perimenopausal women with irregular bleeding fall in a gap between the two.
  • A full thyroid panel (including free T3, reverse T3, and TPO antibodies) is more diagnostically informative than TSH alone in this population.
  • Magnesium glycinate, selenium, zinc, and pyridoxal-5-phosphate address the neuromuscular and dopaminergic mechanisms underlying RLS and are frequently suboptimal in this overlap group.
  • Treating RLS and thyroid dysfunction in isolation is less effective than addressing both simultaneously — the sleep fragmentation caused by RLS actively worsens thyroid regulation through cortisol and TSH pulsatility disruption.

---

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before changing your supplement regimen or thyroid medication.

Written by Jared Murray, Co-Founder & Head of Health Research, Ones.

Jared is the co-founder and head of health research at Ones, with 25 years applying nutrition science, biomarker interpretation, and clinical supplementation research to individual health programs. He leads the editorial process for the Ones Health Library, where lab data, wearable biometrics, and peer-reviewed clinical research are translated into evidence-based, personalized supplement guidance.

Disclosure: Ones formulates and sells personalized supplements that may include ingredients discussed in this article. We have a financial interest in the products mentioned. Recommendations are based on published research and our editorial standards, not sales targets.

This article is educational content, not medical advice. Consult a healthcare provider before changing your supplement regimen.

Further reading

Related reading